Literature DB >> 10570792

Pharmaceutically active secondary metabolites of microorganisms.

A L Demain1.   

Abstract

The antibiotics have been useful in our battles against infectious bacteria and fungi for over 50 years. However, many antibiotics are used commercially, or are potentially useful, in medicine for activities other than their antibiotic action. They are used as antitumor agents, immunosuppressive agents, hypocholesterolemic agents, enzyme inhibitors, antimigraine agents, and antiparasitic agents. A number of these products were first discovered as antibiotics which failed in their development as such, or as mycotoxins. In addition to the above alternative applications, new powerful antibiotics have been discovered and commercialized in recent years and others are in clinical testing at the moment. A few successful secondary metabolites appear to have no antibiotic activity. The recently increased development of resistance to older antibacterial and antifungal drugs is being met with the use or clinical testing of older, underutilized or previously nondeveloped narrow-spectrum antibacterial products as well as powerful semisynthetic antifungal agents.

Mesh:

Substances:

Year:  1999        PMID: 10570792     DOI: 10.1007/s002530051546

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  61 in total

1.  Use of direct-infusion electrospray mass spectrometry to guide empirical development of improved conditions for expression of secondary metabolites from actinomycetes.

Authors:  J A Zahn; R E Higgs; M D Hilton
Journal:  Appl Environ Microbiol       Date:  2001-01       Impact factor: 4.792

Review 2.  Possibility of bacterial recruitment of plant genes associated with the biosynthesis of secondary metabolites.

Authors:  Helge Björn Bode; Rolf Müller
Journal:  Plant Physiol       Date:  2003-07       Impact factor: 8.340

3.  Reverse biological engineering of hrdB to enhance the production of avermectins in an industrial strain of Streptomyces avermitilis.

Authors:  Ying Zhuo; Wenquan Zhang; Difei Chen; Hong Gao; Jun Tao; Mei Liu; Zhongxuan Gou; Xianlong Zhou; Bang-Ce Ye; Qing Zhang; Siliang Zhang; Li-Xin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 4.  Development of antibiotics and the future of marine microorganisms to stem the tide of antibiotic resistance.

Authors:  Noer Kasanah; Mark T Hamann
Journal:  Curr Opin Investig Drugs       Date:  2004-08

Review 5.  From natural products discovery to commercialization: a success story.

Authors:  Arnold L Demain
Journal:  J Ind Microbiol Biotechnol       Date:  2006-01-10       Impact factor: 3.346

Review 6.  Triggers and cues that activate antibiotic production by actinomycetes.

Authors:  Hua Zhu; Stephanie K Sandiford; Gilles P van Wezel
Journal:  J Ind Microbiol Biotechnol       Date:  2013-08-02       Impact factor: 3.346

Review 7.  Diversifying carotenoid biosynthetic pathways by directed evolution.

Authors:  Daisuke Umeno; Alexander V Tobias; Frances H Arnold
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

8.  Broad-spectrum antimicrobial epiphytic and endophytic fungi from marine organisms: isolation, bioassay and taxonomy.

Authors:  Yi Zhang; Jun Mu; Yan Feng; Yue Kang; Jia Zhang; Peng-Juan Gu; Yu Wang; Li-Fang Ma; Yan-Hua Zhu
Journal:  Mar Drugs       Date:  2009-04-17       Impact factor: 5.118

9.  Chromosomal instability in Streptomyces avermitilis: major deletion in the central region and stable circularized chromosome.

Authors:  Wei Chen; Fei He; Xiaojuan Zhang; Zhi Chen; Ying Wen; Jilun Li
Journal:  BMC Microbiol       Date:  2010-07-26       Impact factor: 3.605

10.  Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity.

Authors:  William R Schwan; Craig Dunek; Michael Gebhardt; Kathleen Engelbrecht; Tiffany Klett; Aaron Monte; Joseph Toce; Marc Rott; Thomas J Volk; John J LiPuma; Xue-Ting Liu; Ronald McKelvey
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-21       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.